Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 90-97

  Yang, Ping ^a   Kulig, Kimary ^b   Boland, Jennifer M ^b   Erickson Johnson, Michele R ^b   Oliveira, Andre M ^b   Wampfler, Jason ^b   Jatoi, Aminah ^b   Deschamps, Claude ^b   Marks, Randolph ^b   Fortner, Connie ^b   Stoddard, Shawn ^b   Nichols, Francis ^b   Molina, Julian ^b   Aubry, Marie Christine ^b   Tang, Hui ^b   Yi, Eunhee S ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

EML4 anaplastic lymphoma kinase; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung cancer; Progression and recurrence free survival

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ADULT; AGE; AGED; ALGORITHM; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 84655170204     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823c5c32     Document Type: Article

References (25)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in on-small-cell lung cancer. Nature 2007;448: 561-566. (Pubitemid 47206930)
2. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011;6:905-912.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131: 1190-1203. (Pubitemid 350235027)
4. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
5. Wong DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117:2709-2718.
6. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
7. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-897.
8. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol 2009;27:4247-4253.
9. Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancer from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
10. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
11. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010;16:4938-4945.
12. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in NSCLC: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
13. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997-2003. Chest 2005;128:452-462. (Pubitemid 40994510)
14. Visbal AL, Williams BA, Nichols FC, et al. Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997-2002. Ann Thorac Surg 2004;78:209-215. (Pubitemid 38842439)
15. Sugimura H, Nichols FC, Yang P, et al. Survival following recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-418. (Pubitemid 46135441)
16. Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006;81:1021-1027. (Pubitemid 43247679)
17. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-1158.
18. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661-670.
19. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
20. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
21. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011; 6:774-780.
22. Lee JO, Kim TM, Lee SH, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474-1480.
23. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in advance NSCLC harboring anaplastic lymphoma kinase gene rearrangement: A retrospective analysis. Lancet Oncol 2011;11:1004-1012.
24. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
25. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000;53:445-450. (Pubitemid 30396466)